News

Glistenings are common in the hydrophobic acrylic material of certain foldable IOLs, but they are not visually significant.

Consent forms signed before refractive surgery procedures do not suffice as evidence of informed consent.

The author tackles the issue of medical errors from a unique perspective.

Dog bite injuries frequently affect the periocular area, and clinicians should be familiar with the clinical examination, as well as the surgical and medical management paths to take in such cases.

Accumulation of toxins in the retina resulting from environmental and/or genetic factors causes retinal degeneration.

Local therapy with intravitreal sustained-release implants may have a place in the management of ocular infectious and inflammatory diseases, especially when the benefits are weighed against those involved with systemic therapy for patients.

A rebate Genentech offers large-volume purchasers of its ranibizumab has stirred debate over the propriety of rewarding physicians for treating their patients with expensive drugs.

The quality of communication between ophthalmologists and their patients with glaucoma can be improved by physician education.

Implantable lenses may be a viable option for vision correction in patients with high myopia, and in those who have thin corneas or conditions that might predispose them to complications with LASIK.

Mydriatic eye drops do not seem to affect cognitive function, based on results of cognitive testing.

Staggered management- consisting of medical therapy, argon laser, and cyclopexy - is beneficial in patients with cyclodialysis cleft.

The annual American Society of Cataract and Refractive Surgery Symposium on Cataract, IOL, and Refractive Surgery will be held here Friday, March 25, to Tuesday, March 29.

As a busy eye-care facility, Clayton Eye Center in Morrow, GA, employs four ophthalmologists and seven optometrists who see as many as 200 patients daily.

Although many treatments have been tried, there remain no proven effective therapies to treat nonarteritic anterior ischemic optic neuropathy.

Prevent Blindness America (PBA) has commended the recent recommendation by the U.S. Preventive Services Task Force (USPSTF) for vision screening of all children aged 3 to 5 years. The USPSTF recommendation updates the task force?s 2004 recommendation of vision screening for all children aged fewer than 5 years. The USPSTF now recommends vision screening for the presence of amblyopia and its risk factors for all children aged 3 to 5 years.

After many years as a partner and supporter of Prevent Blindness America (PBA), Allergan Inc. has awarded PBA an advocacy grant to provide funding for The Eye Care Advocacy Network (Eye CAN).

Dipak Panigrahi, MD, senior vice president, research and development, and chief medical officer of QLT has stepped down from his position with QLT.

Prevent Blindness America (PBA) held its 6th annual "Eyes on Capitol Hill" event on March 2. This annual event was designed to give community leaders and patient advocates the opportunity to meet with government representatives to discuss vision issues.

The State Food and Drug Administration (SFDA) of China has granted Oculus GmbH SFDA certification for the HR version of its Pentacam camera. As the first rotating Scheimpflug camera on the world market, this camera provides 3-dimensional views of the anterior segment. This certification allows full marketing and sales of this instrument in thee People's Republic of China.

A line of photochromic performance sunwear (SOLFX, Transitions) debuted to more than 40,000 Professional Golfers' Association (PGA) of America and Ladies Professional Golf Association officials; retail and equipment buyers; golf course owners, managers, and developers; and golf instructors at the 2011 PGA Merchandise Show Jan. 26 to 29 in Orlando.

The FDA has granted final approval to Hi-Tech Pharmacal Co. Inc. for the company's abbreviated new drug application for levofloxacin ophthalmic solution 0.5%, the generic for a proprietary ophthalmic solution (Quixin, Vistakon). The product is indicated for bacterial conjunctivitis.

Inspire Pharmaceuticals is undertaking a corporate restructuring designed to allow the company to focus on its eye-care business.

Sanofi-Aventis, a multinational pharmaceutical company headquartered in Paris, is reportedly exploring the possibility of making four acquisitions in the ophthalmology sector totaling $1.35 billion, according to the French newspaper Les Echos. According to the newspaper, which cited unnamed sources, three of the targeted companies are based in the United States, and the fourth one is based in Israel.

Last week?s Ophthalmology Times e-News erroneously reported that Transitions Optical?s Spanish-language courses, to be offered during International Vision Expo East, were approved for American Board of Ophthalmology credit. Rather, the courses are approved for American Board of Opticianry credit.

A line of photochromic performance sunwear (SOLFX, Transitions) debuted to more than 40,000 Professional Golfers? Association (PGA) of America and Ladies Professional Golf Association officials; retail and equipment buyers; golf course owners, managers, and developers; and golf instructors at the 2011 PGA Merchandise Show Jan. 26 to 29 in Orlando.

The International Vision Expo East, slated for March 16 to 20 at the Jacob K. Javits Center in New York City, will include more than 55 hours of courses on managing for profitability and using technology.

A once-daily formulation of bromfenac ophthalmic solution 0.09% (Bromday, ISTA Pharmaceuticals) has been adopted quickly, so the twice-daily formulation of the (Xibrom, ISTA Pharmaceuticals) will be discontinued, according to the company.

QLT Inc. has halted a randomized, placebo-controlled, double-masked phase II proof-of-concept trial of an olopatadine (Patanol, Alcon) punctal plug delivery system (O-PPDS) after the study model ?could not generate definitive clinical results,? according to company officials.

The primary endpoint has been met in one of two phase 3 studies evaluating monthly ranibizumab injection (Lucentis, Genentech) in patients with diabetic macular edema (DME), according to the company.

"The Glaucoma Research Foundation (GRF) ?applauded those who give? at its annual benefit and celebration Jan. 26. The theme of this year?s dinner, auction, and presentations was ?Applauding Those Who Give,? and the benefit focused on recent results from GRF-funded research and the donors who made it possible. "